Pharvaris N.V. (PHVS)
NASDAQ: PHVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
PHVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.22B
- EPS (TTM)
- -$3.06
- Dividend yield
- None
- 52-week range
- 20.65 – 43.25
- Day range
- 30.58 – 32.08
- Volume / Avg
- 341.84K / 740.93K
- Beta
- —
- Shares outstanding
- 70.20M
52-week range
PHVS stock today
Pharvaris N.V. (PHVS) closed at $31.68 on Oct 7, up 1.80% (+$0.56), versus the S&P 500's 0.22% decline. Trading was light, with 341.84K shares changing hands, about 46% of the average daily volume. Shares are 26.8% below their 52-week high of $43.25, set on Sep 8, 2026 and 53.4% above the 52-week low of $20.65, in the middle of the past year's range.
PHVS is up 14.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 41.2%. Pharvaris N.V. has posted a net loss over the last twelve months (EPS of -$3.06), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Pharvaris N.V.
Company profilePharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Berndt Axel Edvard Modig CPA, M.B.A.
- Headquarters
- Zug
- Employees
- 148
- IPO year
- 2021
- Website
- pharvaris.com
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$57.22+80.62%
- Strong buy 3
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Pharvaris N.V. peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMNMImmunome Inc. | 19.10 | -1.11% | $2.25B | vs PHVS |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs PHVS |
| VERAVera Therapeutics Inc. Class A | 30.25 | +2.82% | $2.18B | vs PHVS |
| SLSSELLAS Life Sciences Group Inc. | 11.31 | -0.26% | $2.28B | vs PHVS |
| HRMYHarmony Biosciences Holdings Inc. | 39.34 | -0.05% | $2.29B | vs PHVS |
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs PHVS |
| AUPHAurinia Pharmaceuticals Inc | 16.01 | +2.04% | $2.13B | vs PHVS |
| IRONDisc Medicine Inc. | 61.18 | -0.76% | $2.35B | vs PHVS |
Indexes, lists and sector
Pharvaris N.V. stock FAQ
What is Pharvaris N.V.'s stock price today?
PHVS last traded at $31.68 as of Oct 7, 4:00 PM EDT, up 1.80% on the day. Prices are delayed at least 15 minutes.
Who is Pharvaris N.V.'s CEO?
Mr. Berndt Axel Edvard Modig CPA, M.B.A. is the chief executive officer of Pharvaris N.V., which has about 148 employees.
What is the PHVS 52-week high?
The 52-week high for PHVS is $43.25 and the 52-week low is $20.65. The stock is currently 26.8% below its high.